 |
PAGE 3 OF 3
|
|
|
|
(continued)
|
|
JEAN DUBUISSON
Institut Pasteur of Lille
Lille, France
|
|
LÁSZLÓ NAGY*
University of Debrecen Medical and Health Sciences Center
Debrecen, Hungary
|
|
B. BRETT FINLAY*
University of British Columbia
Vancouver, Canada
|
|
MIGUEL NAVARRO
Consejo Superior de Investigaciones Cientificas
Granada, Spain
|
|
SIMON JAMES FOOTE
The Menzies Research Institute
Hobart, Australia
|
|
SERGEI A. NEDOSPASOV*
Moscow State University
Moscow, Russia
|
|
ANDREA VANESA GAMARNIK
Fundación Instituto Leloir
Buenos Aires, Argentina
|
|
RAFAEL RADI*
Facultad de Medicina, Universidad de la República
Montevideo, Uruguay
|
|
RAJESH S. GOKHALE
National Institute of Immunology
New Delhi, India
|
|
ISABEL RODITI
University of Bern
Bern, Switzerland
|
|
H. ULRICH GÖRINGER*
Darmstadt Technical University
Darmstadt, Germany
|
|
PHILIPPE J. SANSONETTI*
Institut Pasteur
Paris, France
|
|
EMANUEL HANSKI
Hebrew University
Jerusalem, Israel
|
|
D. LOUIS SCHOFIELD*
The Walter and Eliza Hall Institute of Medical Research
Melbourne, Australia
|
|
WILLIAM ROSS HEATH*
The Walter and Eliza Hall Institute of Medical Research
Melbourne, Australia
|
|
DOMINIQUE SOLDATI-FAVRE*
University of Geneva
Geneva, Switzerland
|
|
ANJA TATIANA RAMSTEDT JENSEN
University of Copenhagen
Copenhagen, Denmark
|
|
NATALIE C. J. STRYNADKA*
University of British Columbia
Vancouver, Canada
|
|
SUMALEE KAMCHONWONGPAISAN
National Center for Genetic Engineering and Biotechnology
Pathumthani, Thailand
|
|
SANTUZA M.R. TEIXEIRA
Federal University of Minas Gerais
Minas Gerais, Brazil
|
|
ELENA A. LEVASHINA
Institut de Biologie Moleculaire et Cellulaire
Strasbourg, France
|
|
GISOU F. VAN DER GOOT
University of Geneva
Geneva, Switzerland
|
|
* Indicates renewed support for a previous HHMI international research scholar
|
|
|
|
|
|
 |
|
|
|
|
|
Three HHMI investigators and two HHMI international research scholars at universities in the United States, Canada, and the United Kingdom will lead projects that have been offered grants—aimed at creating effective health tools in developing countries—totaling $57 million.
The grants are part of an international effort launched in 2003 by the Bill & Melinda Gates Foundation in partnership with the National Institutes of Health. This initiative focuses on 14 main scientific and technological challenges that, if met, could have a profound impact on improving health in the world's poorest countries. Key goals are to devise new ways to test the safety of potential vaccines, better understand how the body naturally fights infection, and incapacitate disease-carrying insects.
Among the HHMI awardees is Richard A. Flavell, an HHMI investigator at Yale University. He and colleagues have been offered $17 million to develop laboratory mice whose immune systems are similar enough to humans to allow testing of human vaccines. George M. Shaw, an HHMI investigator at the University of Alabama at Birmingham School of Medicine, will lead a team offered $16.3 million to study how the immune systems of patients with HIV change as they are infected by and respond to the virus, as well as corresponding changes in the virus itself. HHMI investigator Richard Axel and two HHMI international research scholars, B. Brett Finlay and Adrian Vivian Hill, also received support.
FOR MORE INFORMATION
Including brief descriptions of the HHMI scientists' projects, visit www.hhmi.org/news/062805.html.
|
|
|
|
|
|
|
|
|
|
|
|
Back
